The impact of gender differences in P-glycoprotein function measured with [18F]MC225 and PET

The impact of gender differences in P-glycoprotein function measured with [18F]MC225 and PET - Genderdifferences in P-gp function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53850

Enrollment

Registered

2023-04-12

Start date

2023-01-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transporterfunctie op de bloed-hersenbarriere genderdifferences

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age: 50-80 years - MMSE: 28-30 - No history of any neuropsychiatric disorders that might affect the P-gp function or blood-brain barrier integrity

Exclusion criteria

Exclusion criteria: - Use of medication with known P-gp affinity - History of neuropsychiatric disorders affecting the P-gp function or blood-brain barrier integrity

Design outcomes

Primary

Measure	Time frame
PET images will be analysed using PMOD software (PMOD technologies, Zurich, Switzerland, version 4.1). Predefined brain regions based on a maximum probability map are selected as volumes of interest (VOIs). Tracer kinetics of [18F]MC225 reflect the BBB P-gp function and will be assessed as outcome measure for P-gp efflux function. Those will be compared in between the groups of male and female subjects.	—

Measure

Time frame

PET images will be analysed using PMOD software (PMOD technologies, Zurich, Switzerland, version 4.1). Predefined brain regions based on a maximum probability map are selected as volumes of interest (VOIs). Tracer kinetics of [18F]MC225 reflect the BBB P-gp function and will be assessed as outcome measure for P-gp efflux function. Those will be compared in between the groups of male and female subjects.

—

Countries

Netherlands

Outcome results